Sonnet BioTherapeutics Holdings, Inc.

NasdaqCM SONN

Sonnet BioTherapeutics Holdings, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 0.50

Sonnet BioTherapeutics Holdings, Inc. Price to Sales Ratio (P/S) is 0.50 on January 14, 2025, a -99.28% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Sonnet BioTherapeutics Holdings, Inc. 52-week high Price to Sales Ratio (P/S) is 146.76 on April 08, 2024, which is 29,100.20% above the current Price to Sales Ratio (P/S).
Sonnet BioTherapeutics Holdings, Inc. 52-week low Price to Sales Ratio (P/S) is 0.48 on December 24, 2024, which is -5.33% below the current Price to Sales Ratio (P/S).
Sonnet BioTherapeutics Holdings, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 87.34.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: SONN

Sonnet BioTherapeutics Holdings, Inc.

CEO	Dr. Pankaj Mohan Ph.D.
IPO Date	Oct. 31, 2006
Location	United States
Headquarters	100 Overlook Center
Employees	12
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Key trends

Past 5 years